絞り込み

16404

広告

神戸マラソンに約2万人 健脚競う (NHK)

阪神・淡路大震災で受けた支援への感謝と復興した町の様子を伝えようと始まった神戸マラソンが19日に行われ、およそ2万人が健脚を競いました。 神戸マラソンはことしで...

  1. 食物アレルギー 治療や検査で9人が重い症...
  2. 冬の登山に注意を 富士山登山道で呼びかけ...
  3. 歴史教科書、龍馬が消える? 高校の用語半...
  4. クルマ社会に革新をもたらす10の「注目ス...

ニュース一覧

Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.

著者 Camm AJ , Fox KAA , Peterson E
Europace.2017 Oct 13 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (27view , 0users)

Full Text Sources

Miscellaneous

The aim of this review is to provide context for meta-analyses interpreting data from phase III stroke prevention studies of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation (NVAF). Differences between the four phase III NOAC stroke prevention studies in patients with NVAF (ROCKET AF, ARISTOTLE, RE-LY, and ENGAGE AF), their potential impact on outcomes, and inter-study differences were evaluated, as well as the potential role of real-world evidence in evaluating NOACs in this setting. Study design differences included blinding strategy, dose-reduction options, and transition from blinded treatment to standard of care. There were small but relevant variations in the definition of AF used (RE-LY used the least precise definition); patient risk profiles (ROCKET AF patients had the highest risk); the primary safety outcome (a composite of major bleeding and clinically relevant non-major bleeding events in ROCKET AF vs. major bleeding in the others); and the definitions of stroke, major bleeding, and clinically relevant non-major bleeding events. In real-world studies, methodological variations and biases are amplified, making cross-study comparisons and meta-analyses problematic. Because of these methodological differences, meta-analyses of phase III studies need to be robust, and if outcomes of the reference (warfarin-treated) arms differ significantly, the basis of the meta-analysis is not strong. These key issues need to be taken into consideration for direct comparisons across studies, and for the interpretation of meta-analytic data.
PMID: 29040518 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード